Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
GLP-1 (, ),
J Diabetes Res 2018:1232583 Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V (2020) Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment
Patients should ask specific questions about any proposed treatments: What is the evidence supporting this treatment for my condition
Last but not least, by reducing the dose and avoiding systemic distribution, nasal delivery of GLP-1 drugs should alleviate gastrointestinal and other adverse events, offering a promising approach for maximizing the therapeutic effects GLP-1 drugs with potentially increased compliance and safety
Kohe SE, Bennett CD, Gill SK, Wilson M, McConville C, Peet AC
US$ 22.02
US$ 27.11
US$ 21.68
US$ 23.43
US$ 27.31
US$ 27.15
US$ 25.27
US$ 21.14
